## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.8% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($28.19)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Key facts: French study confirms Moderna vaccine reduces COVID-19 deaths; Moderna to present at J.P. Morgan Healthcare Conference**
- Source: TradingView â€” Track All Markets | 20251217T200812 | Bullish | Relevance: 100%
- A French study has confirmed the efficacy and safety of Moderna's COVID-19 vaccine, showing a 75% reduction in COVID-19 deaths for vaccinated individuals compared to unvaccinated ones. Additionally, Moderna, Inc. (MRNA) is scheduled to present at the J.P. Morgan Healthcare Conference on January 12, 2026, which will include a live webcast.

**2. Moderna (MRNA) Stock Trades Up, Here Is Why**
- Source: Finviz | 20251217T183721 | Bullish | Relevance: 100%
- Shares of biotechnology company Moderna (MRNA) jumped 4% due to a strong rebound in the broader biotech sector, driven by positive clinical data, successful new drug launches, and increased M&A activity. RBC Capital Markets noted a significant rise in M&A deals compared to the previous year, with further deal-making expected. Additionally, Moderna announced its upcoming presentation at the 44th annual J.P. Morgan Healthcare Conference in January.

**3. Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma**
- Source: Erie Times-News | 20251216T140824 | Bullish | Relevance: 100%
- Moderna has announced that the first patient has been dosed in a Phase 1/2 study for mRNA-2808, an investigational mRNA-based T-cell engager aimed at treating relapsed or refractory multiple myeloma. This marks a significant milestone as it is Moderna's first T-cell engager therapy to enter clinical trials, utilizing a multiplexed approach to target tumor heterogeneity and overcome resistance. The study, conducted in collaboration with Sarah Cannon Research Institute, will evaluate the safety and tolerability of mRNA-2808 in adult patients.

**4. EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)**
- Source: Cape Cod Times | 20251216T110826 | Bullish | Relevance: 100%
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Moderna's new COVID vaccine, mNEXSPIKE (mRNA-1283), for individuals aged 12 and older. This recommendation, following positive Phase 3 clinical trial results, positions mNEXSPIKE as Moderna's third product to receive a positive CHMP opinion in Europe, aiming to address the ongoing public health need for targeted COVID-19 protection. The European Commission will now make a final marketing authorization decision, with Moderna anticipating mNEXSPIKE's availability in Europe, subject to regulatory timelines.

**5. EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)**
- Source: The Northwest Florida Daily News | 20251216T070922 | Bullish | Relevance: 100%
- The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Moderna's mNEXSPIKE (mRNA-1283) COVID-19 vaccine for individuals aged 12 and older. This recommendation is based on Phase 3 trial results showing mNEXSPIKE had a higher relative vaccine efficacy compared to Spikevax, especially in older adults, and a similar safety profile. Subject to European Commission authorization, this marks Moderna's third product recommended by the CHMP, aiming to address ongoing public health needs and drive sales growth in Europe.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $28 | $30 | -7% |
| 2025-12-12 | Jefferies | $30 | $0 | 0% |
| 2025-11-21 | Piper Sandler | $63 | $69 | -9% |
| 2025-11-21 | RBC Capital | $25 | $28 | -11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Jefferies | init | Hold |
| 2025-11-21 | Piper Sandler | reit | Overweight |
| 2025-11-21 | RBC Capital | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. High short interest (21.2%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.61 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.1B |
| Beta | 1.11 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.61 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 10.1% to 6.8% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (6.8% > 6.0%), caution on chasing. MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 6.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 71, risk of mean reversion. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.82% (CS: 98) | Strong |
| RSI_14 | 70.8 | Overbought |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.150x | Above |
| vs SMA50 | 1.176x | Above |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $30.95
- **Stop Loss:** $28.19 (8.9% risk)
- **Target:** $33.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 344
- **Position Value:** $10,646.80
- **Portfolio %:** 10.65%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*